Merck at The AAN

Merck will be presenting data for MAVENCLAD® (Cladribine Tablets) a treatment for highly active relapsing multiple sclerosis (RMS) as defined by clinical or imaging features, and Rebif®(interferon beta-1a) at the American Academy of Neurology (AAN) 70th Annual Meeting, April 21-27, 2018, in Los Angeles.

MAVENCLAD® data to be presented includes poster presentations highlighting post-hoc analyses of the CLARITY, CLARITY Extension and ORACLE-MS trials evaluating safety and use in patients with multiple sclerosis (MS), as well as the impact on B- and T-cells. MAVENCLAD® is a short-course oral therapy that is thought to preferentially target lymphocytes which may be integral to the pathological process of relapsing forms of MS (RMS). MAVENCLAD® is currently under clinical investigation and is not approved in the US.

MAVENCLAD® has received marketing authorisation in 35 countries including European Union member countries, Canada, Australia, Argentina, Israel, and the United Arab Emirates. MAVENCLAD® is now available in Germany, UK, Canada, Netherlands, Norway, Denmark, Sweden, Israel, and other markets. The Company plans additional filings for regulatory approval in other countries, including the United States.

Rebif data includes presentations analysing no evidence of disease activity (NEDA), long-term disease activity assessed by the Magnetic Resonance Imaging in MS (MAGNIMS) score, new data on pregnancy outcomes for women being treated with interferon beta, as well as real-world evidence evaluating treatment adherence rates for patients treated with Rebif compared with dimethyl fumarate.

We look forward to presenting data demonstrating advancement in our knowledge of MS, including further scientific information about Mavenclad and Rebif at the 2018 AAN Annual Meeting

said Luciano Rossetti, Head of Global R&D for the biopharma business of Merck.

Meeting attendees can learn more about the Company and participate in the following MS-specific interactive activities by visiting booth #1847:

• “I’m Balancing MS”: Individuals can understand the balance between healthcare and lifestyle for those facing MS through a mobile art activity. For each participant, we will donate $100 to MS Fitness Challenge, a charity organisation dedicated to educating and training people with MS on the benefits of exercise and nutrition.
•  “Shine a Light”: Individuals can create their own Light Trail art symbolising what drives their commitment to fighting MS. Participation in the activity will drive a donation to MS Fitness Challenge.

Additionally, Exhibit Hall booth #1957 will host hands-on activities which will allow attendees to gain a better understanding of what it’s like to have MS through virtual reality pods and simulation stations.

The company will also be hosting an Industry Therapeutic Update event entitled Evolving Perspectives and Innovations in Multiple Sclerosis on Wednesday, April 25 from 7:00 p.m.-10:00 pm PDT at the Platinum Ballroom in the JW Marriott Hotel in Los Angeles. Speakers include, Professor Amit Bar-Or, University of Pennsylvania, Philadelphia, PA, Professor Dusan Stefoski, Rush University Medical Center, Chicago, IL and Professor Anthony Traboulsee, University of British Columbia, Vancouver, CA.

AAN Brain Health Fair

The MS InsideOut experience will be exhibited at the AAN Brain Health Fair, a one-day-only event where attendees can learn about the brain and the field of neurology. The event takes place on Friday, April 20 from 10:00 a.m.-4:00 pm PDT at the Los Angeles Convention Center.

Presentations at AAN 2018 include the following accepted abstracts:

Full session details and data presentation listings for the 2018 AAN Annual Meeting can be found at the meeting website: https://www.aan.com/conferences-community/annual-meeting